Current Report Filing (8-k)
October 14 2022 - 04:11PM
Edgar (US Regulatory)
0001622879 false 0001622879 2022-10-12
2022-10-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934
Date of Report (Date of earliest event reported):
October 12, 2022
Medicine Man Technologies, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Nevada |
000-55450 |
46-5289499 |
(State
or Other Jurisdiction of
Incorporation) |
(Commission File Number) |
(IRS
Employer Identification No.) |
|
4880 Havana Street,
Suite 201
Denver,
Colorado
|
|
80239 |
| (Address of Principal Executive
Offices) |
|
(Zip
Code) |
| |
|
|
| (303)
371-0387 |
| (Registrant’s Telephone Number, Including Area
Code) |
| |
|
|
| Not Applicable |
| (Former Name or Former Address, if Changed Since
Last Report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of Each
Class |
|
Trading Symbol(s) |
|
Name of Each Exchange On Which
Registered |
| Not
applicable |
|
Not
applicable |
|
Not
applicable |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On October 12, 2022 Nirup Krishnamurthy became President of
Medicine Man Technologies, Inc. (the “Company”).
Mr. Krishnamurthy had been the Company’s Chief Operating
Officer, a position that will not be filled immediately.
Mr. Krishnamurthy will continue to report directly to Justin
Dye, Chairman and CEO of the Company. The Company’s Executive
Leadership Team will report directly to Mr. Krishnamurthy.
Mr. Krishnamurthy’s annual salary increased to $325,000 and he
was granted options to purchase 200,000 shares of the Company’s
common stock at an exercise price of $1.24 per share, vesting in
four equal annual installments on the first, second, third, and
fourth anniversary of the date of grant.
Also on October 12, 2022, Nancy Huber, the Company’s Chief
Financial Officer, announced that she will be retiring from the
Company due to personal reasons. Ms. Huber will remain with
the Company as Chief Financial Officer for an indefinite period of
time while a search for her replacement is conducted.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
MEDICINE MAN
TECHNOLOGIES, INC. |
| |
|
| |
By: |
/s/ Daniel R. Pabon |
|
|
Daniel R. Pabon
General Counsel |
| |
|
|
| Date: October 14, 2022 |
|
|
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From Jan 2023 to Feb 2023
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From Feb 2022 to Feb 2023
